2025-01-03 The Registration Clinical Study Conducted in China of the Global Innovative Temperature-Sensitive Embolic Agent Has Completed the First Patient Enrollment

2024-12-31 Grand Pharma’s Cardiovascular and Cerebrovascular Precision Interventional Diagnostics Segment Receives Approvals for Three Major Products

2024-12-30 Grand Pharma Fuchi Industrial Park Successfully Evaluated as Class D Park, Opening a New Chapter of Safety Development

2024-12-17 NDA for a Global Innovative Product of the Group Treated for Demodex Blepharitis Has Been Accepted by NMPA

2024-12-14 Grand Pharma’s world-first innovation for dry eye enters Chinese Expert Consensus on the Diagnosis and Treatment of Dry Eye (2024)

2024-12-14 The Phase II Clinical Study in China of Grand Pharma’s Global Innovative Product STC3141 Has Completed the Enrollment of All Patients

2024-12-13 Grand Pharma’s Global Innovative Intravascular Dual-Mode Imaging System NOVASYNC Was Approved by NMPA for Commercialization in China

2024-12-12 Grand Pharma Acquires Exclusive Development and Commercialisation Rights to World’s First Innovative Product for the Treatment of Dry Eye Disease

2024-12-02 The Phase III Clinical Study Conducted in China of the Global Innovative RDC TLX250-CDX Has Completed the First Patient Enrollment and Dosing

2024-11-05 The Phase III Clinical Study of the Group’s Global Innovative Ophthalmic Drug GPN00833 Conducted in China Has Completed and Has Successfully Met Clinical Endpoint

2024-10-31 Grand Pharma Presents at the 21st National Academic Meeting of Chinese Society of Otolaryngology-Head and Neck Surgery

2024-10-28 The First Adjustable Intracranial Stent Retriever Product That Produced in China of the Group Was Approved for Commercialization by NMPA